The US Food and Drug Administration has approved Botox for treating overactive bladder in adult patients who have failed to respond to other treatments or are unable to tolerate them.
Botox, manufactured by Allergen Inc, was initially developed as a cosmetic procedure but has since been approved in treating various conditions, including migraines, chronic focal neuropathies and squints.
Now a number of studies have found Botox to be beneficial in treating overactive bladder in adults.
"Clinical studies have demonstrated Botox's ability to significantly reduce the frequency of urinary incontinence. Today's approval provides an important additional treatment option for patients with overactive bladder, a condition that affects an estimated 33 million men and women in the United States", the director of the FDA's Division of Reproductive and Urologic Products, Hylton Joffe said.